Bard PowerPort Catheter

FDA Class I Recall Issued for Arrow International Kits Over Drug Quality Concerns

Published Jul 12, 2026Updated Jul 12, 2026

By People's Justice

What happened

The FDA issued a Class I recall against Arrow International, LLC after kits and sets were found to contain drugs — including Lidocaine, Bupivacaine, and 0.9% sodium chloride — sourced from a supplier with identified quality issues. The agency noted limited reports of drug ineffectiveness and warned that compromised sterility in a water-based injectable product could lead to serious health consequences. This recall was detected on June 30, 2026.

Event date: Jun 30, 2026

Source: api.fda.gov

Bard PowerPort Catheter case guide Check eligibility

Related news

Oct 3, 2026
Bard PowerPort Catheter
Judge Denies Bard's Bid to Dismiss Port Catheter Bellwether Case
The federal judge overseeing the Bard PowerPort multidistrict litigation in Arizona denied a motion for summary judgment filed by C.R. Bard Inc. and Becton Dickinson and Co., allowing a woman's design-defect claims to proceed to the third bellwether trial in the MDL, according to Mealey's and Bloomberg Law.
Source: mealeys.com
Sep 30, 2026
Bard PowerPort Catheter
FDA Issues Class I Recall for Bard Power-Trialysis Dialysis Catheter
The FDA logged a Class I recall for Bard Access Systems' Power-Trialysis Short-Term Straight Dialysis Catheter (REF 5605150). The agency's database describes this as a downstream recall tied to an earlier Class I recall, RES 98777.
Source: api.fda.gov
Sep 29, 2026
Bard PowerPort Catheter
FDA Lists Class I Recall for Bard Power-Trialysis Catheter
The FDA's enforcement database lists a Class I recall for the Bard Access Systems Power-Trialysis Short-Term Straight Dialysis Catheter (REF 5605150), identified as a downstream recall tied to an earlier recall event, RES 98777.
Source: api.fda.gov